慢性淋巴细胞白血病 (CLL) 治疗方案
权威癌症研究机构美国国家癌症研究所 (NCI)对慢性淋巴细胞白血病 （复发性或难治性慢性淋巴细胞白血病 (CLL) ）治疗方案：阿仑单抗（Campath）。
阿仑单抗（Campath）治疗慢性淋巴细胞白血病 （复发性或难治性慢性淋巴细胞白血病 (CLL) ）医学证据
阿仑单抗是一种针对CD52的单克隆抗体，在治疗化疗耐药疾病或具有del（17p）或TP53突变的高危未治疗患者时显示出活性。[1-3]作为单一药物，阿仑单抗的皮下给药途径优于静脉给药途径，因为其疗效相似，不良反应减少，包括一些非随机报告中显示的较轻的急性过敏反应。[2-3]
在联合方案中，皮下注射阿仑单抗加氟达拉滨（含或不含环磷酰胺）或静脉注射阿仑单抗加烷基化剂会导致过量的感染毒性和死亡，在三个II期试验和一个随机试验中，疗效没有代偿性改善。[4-5][证据级别：3iiiDiv]；[6][证据级别：1IDIII]
参考资料：
[1]Moreton P, Kennedy B, Lucas G, et al.: Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23 (13): 2971-9, 2005.
[2]Pettitt AR, Jackson R, Carruthers S, et al.: Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. J Clin Oncol 30 (14): 1647-55, 2012.
[3]Gritti G, Reda G, Maura F, et al.: Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia. Leuk Lymphoma 53 (3): 424-9, 2012.
[4]Lin TS, Donohue KA, Byrd JC, et al.: Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. J Clin Oncol 28 (29): 4500-6, 2010.
[5]Lepretre S, Aurran T, Mahé B, et al.: Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood 119 (22): 5104-10, 2012.
[6]Geisler CH, van T' Veer MB, Jurlander J, et al.: Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL. Blood 123 (21): 3255-62, 2014.
